drugset
drugset / Trial / NCT05560464

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

NCT05560464 ↗

Phase 1 Completed 36 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of multiple doses of VX-584 in participants with mild or moderate hepatic impairment as compared to matched healthy controls.

Timeline

Start
2022-10-14
Primary completion
2023-07-24
Completion
2023-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.